[EN] This invention relates to compounds of formula (I) wherein R<1>, R<2>, R<3>, R<4>, R<5>, R<6> and R<7> are as defined. These compounds exhibit activity as immunostimulants. [FR] Cette invention concerne des composés de formule (I), dans laquelle R1, R2, R3, R4, R5, R6 et R7 sont définis. Ces composés présentent une activité en tant qu'immunostimulants.
[EN] SARS-C0V-2 INACTIVATION BY ETHACRIDINE<br/>[FR] INACTIVATION DE SARS-COV-2 PAR L'ÉTHACRIDINE
申请人:[en]THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
公开号:WO2022093871A1
公开(公告)日:2022-05-05
Herein, existing and approved drugs that were not previously used as antiviral agents are disclosed that may be readily repurposed to treat viral infections, including COVID-19. In a primary implementation, ethacridine and derivatives thereof are utilized in methods of treating viral infections, including COVID-19. Drug delivery devices for administering ethacridine are provided. Also disclosed are novel reporters of SARS-CoV-2 Mpro activity that may be utilized to identify novel agents for treating viral infections such as COVID-19.
Quinoline derivatives as immunostimulants
申请人:Pfizer Inc.
公开号:US05506235A1
公开(公告)日:1996-04-09
This invention relates to compounds of the formula ##STR1## wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6 and R.sup.7 are as defined hereinbelow that exhibit activity as immunostimulants.